BR0214614A - Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2 - Google Patents

Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2

Info

Publication number
BR0214614A
BR0214614A BR0214614-2A BR0214614A BR0214614A BR 0214614 A BR0214614 A BR 0214614A BR 0214614 A BR0214614 A BR 0214614A BR 0214614 A BR0214614 A BR 0214614A
Authority
BR
Brazil
Prior art keywords
selective
methods
bone
receptor agonists
administration
Prior art date
Application number
BR0214614-2A
Other languages
English (en)
Inventor
Francis Dumont
Jinyang Hong
Yesook Kim
Richard Wilker Korsmeyer
Mei Li
Vishwas Madhav Paralkar
David Duane Thompson
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of BR0214614A publication Critical patent/BR0214614A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

"COMPOSIçõES FARMACêUTICAS E MéTODOS PARA A ADMINISTRAçãO DE AGONISTAS SELETIVOS DO RECEPTOR EP~ 2~". Esta invenção refere-se a formulações farmacêuticas e métodos compreendendo agonistas de prostaglandinas, especificamente, agonistas seletivos do receptor EP~ 2~, os quais são proveitosos para melhorar a reparação e cicatrização ósseas e para restabelecer ou aumentar a massa óssea em vertebrados, especialmente em mamíferos. Os agonistas seletivos do receptor EP~ 2~ da presente invenção são eficazes no tratamento de condições tais como aquelas em que o paciente possui um atraso na consolidação de uma fratura ou uma fratura que não consolida, um defeito ósseo, uma fusão vertebral, um encravamento ósseo, uma reconstrução craniofacial, e locais ósseos em risco de fratura.
BR0214614-2A 2001-11-30 2002-10-21 Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2 BR0214614A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US33515601P 2001-11-30 2001-11-30
PCT/IB2002/004368 WO2003045371A1 (en) 2001-11-30 2002-10-21 Pharmaceutical compositions and methods for administering ep2 receptor selective agonists

Publications (1)

Publication Number Publication Date
BR0214614A true BR0214614A (pt) 2004-09-14

Family

ID=23310510

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0214614-2A BR0214614A (pt) 2001-11-30 2002-10-21 Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2

Country Status (24)

Country Link
US (1) US20030166631A1 (pt)
EP (1) EP1448182A1 (pt)
JP (1) JP2005513030A (pt)
KR (1) KR20040063981A (pt)
CN (1) CN1599605A (pt)
AR (1) AR037593A1 (pt)
AU (1) AU2002348948A1 (pt)
BR (1) BR0214614A (pt)
CA (1) CA2468494A1 (pt)
GT (1) GT200200235A (pt)
HN (1) HN2002000336A (pt)
IL (1) IL161834A0 (pt)
MX (1) MXPA04003689A (pt)
NO (1) NO20042272L (pt)
NZ (1) NZ532209A (pt)
PA (1) PA8559601A1 (pt)
PE (1) PE20030660A1 (pt)
PL (1) PL370914A1 (pt)
RU (1) RU2004116318A (pt)
SV (1) SV2004001417A (pt)
TW (1) TW200300342A (pt)
UY (1) UY27556A1 (pt)
WO (1) WO2003045371A1 (pt)
ZA (1) ZA200402795B (pt)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
EP1661580B1 (en) * 2003-07-25 2014-01-08 Ono Pharmaceutical Co., Ltd. Remedy for cartilage-related diseases
WO2005080367A1 (en) * 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
MXPA06015049A (es) 2004-07-08 2007-02-08 Novo Nordisk As Marcadores prolongadores de polipeptidos que comprenden una porcion tetrazol.
JP2009505973A (ja) 2005-08-09 2009-02-12 アステランド ユーケイ リミテッド Ｅｐ２受容体アゴニスト
US7915316B2 (en) * 2005-08-22 2011-03-29 Allergan, Inc Sulfonamides
CA2644851A1 (en) * 2006-03-07 2007-09-13 Osteoscreen Ip, Llc Hmg co-a reductase inhibitor enhancement of bone and cartilage
CA2659184C (en) * 2006-07-28 2012-02-21 Pfizer Products Inc. Ep2 agonists
JP5271272B2 (ja) 2006-11-16 2013-08-21 ジェンムス ファーマ インコーポレイティド Ａ型インフルエンザウィルス感染の治療のための薬剤としてのｅｐ２およびｅｐ４作動薬
CA2982520A1 (en) * 2007-08-21 2009-02-26 Senomyx, Inc. Identification of human t2r receptors that respond to bitter compounds that elicit the bitter taste in compositions, and the use thereof in assays to identify compounds that inhibit (block) bitter taste in compositions and use thereof
EP2149551A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG N-(Indol-3-ylalkyl)-(hetero)arylamidderivate als Modulatoren des EP2-Rezeptors
EP2149552A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma AG 5,6 substituierte Benzamid-Derivate als Modulatoren des EP2-Rezeptors
EP2149554A1 (de) 2008-07-30 2010-02-03 Bayer Schering Pharma Aktiengesellschaft Indolylamide als Modulatoren des EP2-Rezeptors
WO2010116270A1 (en) 2009-04-10 2010-10-14 Pfizer Inc. Ep2/4 agonists
FR3034678A1 (fr) * 2015-04-07 2016-10-14 Geocorail Dispositif, procede et compose pour la reconstruction osseuse d'un vertebre.
CN108883136A (zh) 2016-02-12 2018-11-23 蓝鸟生物公司 Vcn增强子组合物及其使用方法
EP3414321B8 (en) * 2016-02-12 2023-05-03 bluebird bio, Inc. Vcn enhancer compositions and methods of using the same
US12042503B2 (en) 2020-02-12 2024-07-23 Cytoagents, Inc. Compositions and methods for treating coronavirus infections

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4789663A (en) * 1984-07-06 1988-12-06 Collagen Corporation Methods of bone repair using collagen
JP2000507961A (ja) * 1996-12-20 2000-06-27 ファイザー・インク Ｅｐ２受容体サブタイプ選択性のプロスタグランジンｅ２アゴニストによる骨格障害の予防と治療
UA59384C2 (uk) * 1996-12-20 2003-09-15 Пфайзер, Інк. Похідні сульфонамідів та амідів як агоністи простагландину, фармацевтична композиція та способи лікування на їх основі
US6071982A (en) * 1997-04-18 2000-06-06 Cambridge Scientific, Inc. Bioerodible polymeric semi-interpenetrating network alloys for surgical plates and bone cements, and method for making same
UA67754C2 (uk) * 1997-10-10 2004-07-15 Пфайзер, Інк. Агоністи простагландину, фармацевтична композиція на їх основі (варіанти), спосіб нарощення та збереження кісткової маси у хребетних та спосіб лікування (варіанти)
US20010056060A1 (en) * 2000-02-07 2001-12-27 Cameron Kimberly O. Treatment of osteoporsis with EP2/EP4 receptor selective agonists

Also Published As

Publication number Publication date
GT200200235A (es) 2003-06-25
HN2002000336A (es) 2003-02-10
EP1448182A1 (en) 2004-08-25
CN1599605A (zh) 2005-03-23
UY27556A1 (es) 2003-06-30
MXPA04003689A (es) 2004-07-23
KR20040063981A (ko) 2004-07-15
PE20030660A1 (es) 2003-08-04
NZ532209A (en) 2007-05-31
CA2468494A1 (en) 2003-06-05
RU2004116318A (ru) 2005-03-27
IL161834A0 (en) 2005-11-20
SV2004001417A (es) 2004-02-24
AR037593A1 (es) 2004-11-17
WO2003045371A1 (en) 2003-06-05
PA8559601A1 (es) 2003-07-28
US20030166631A1 (en) 2003-09-04
PL370914A1 (en) 2005-06-13
NO20042272L (no) 2004-07-28
AU2002348948A1 (en) 2003-06-10
JP2005513030A (ja) 2005-05-12
ZA200402795B (en) 2005-04-13
TW200300342A (en) 2003-06-01

Similar Documents

Publication Publication Date Title
BR0214614A (pt) Composições farmacêuticas e métodos para a administração de agonistas seletivos de receptor ep2
BR0115687A (pt) Agonistas seletivos do receptor ep4 no tratamento de osteoporose
Larsson et al. Anti-osteoporosis therapy and fracture healing
BR0211888A (pt) Materiais e métodos para promoção de reparo de tecido nervoso
BR0210282A (pt) Veìculos de distribuição de fosfato de cálcio para proteìnas osteoindutivas
Memeo et al. A new way to treat forearm post-traumatic non-union in young patients with intramedullary nailing and platelet-rich plasma
SG148037A1 (en) Fgf variants and methods for use thereof
BR9714155A (pt) Prevenção da perda e reposição da massa óssea por certos agonistas de prostaglandina.
Choi et al. Cellular and molecular characterization of a murine non-union model
YU7797A (sh) Kombinovana terapija za osteoporozu
AP2001002357A0 (en) EP4 receptor selective agonists in the treatment of osteoporosis.
BR9804437A (pt) Compostos para a osteoporose
BR9909445A (pt) Método para aumentar a rigidez e resistência óssea e reduzir fraturas
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
BRPI0812504B8 (pt) composto para profilaxia ou tratamento de doença ou condição associada a receptor de canabinoides em sujeito mamífero
BR112013025048A2 (pt) sistemas de fixação de fratura tendo apoio intramedular
BRPI0417621A (pt) terapia de combinação contìnua com agonistas seletivos do receptor ep4 de prostaglandina e um estrogênio para o tratamento de estados que se apresentem com baixa massa óssea
WO1998058911A3 (en) Prostaglandin agonists
BR0100381A (pt) Tratamento de osteoporose com agonistasseletivos do receptor ep/2/ep4
DE60313004D1 (de) Alpha-7-nikotinsäure-rezeptoragonisten und statine in kombination
BR0310087A (pt) Veìculos sólidos injetáveis para ácido hialurÈnico para aplicação de proteìnas osteogênicas
Von Wilmowsky et al. Reconstruction of a mandibular defect with autogenous, autoclaved bone grafts and tissue engineering: an in vivo pilot study
BR0007892A (pt) Processos e composições para cicatrização ereparo de cartilagem articular
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.
BR9912556A (pt) Triazolpiridinas para o tratamento de distúrbios trombóticos

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADE(S).

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2108 DE 31/05/2011.